SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-termRead More